Utilidad de la toxina botulínica en el tratamiento de migraña crónica
Barra lateral del artículo
Publicado:
Jan 5, 2023
Palabras clave:
Trastornos migrañosos, toxinas botulínicas tipo A, terapéutica, cefalea
Contenido principal del artículo
Resumen
Introducción. La migraña es una de las primeras causas de discapacidad a nivel mundial en el ser humano, con una prevalencia mayor en las mujeres. La toxina botulínica ha mostrado una gran efectividad en el tratamiento de la migraña crónica disminuyendo los días de cefalea. Objetivo. Describir la utilidad de la toxina botulínica en el tratamiento de migraña crónica. Metodología. Se realizó un estudio no experimental de tipo revisión bibliográfica sobre la utilidad de la toxina botulínica en el tratamiento de migraña crónica en la que se emplearon artículos científicos publicados en las bases de datos como Pubmed y Scopus. El período de revisión comprendió los últimos 5 años. Resultados. Se evidencio los beneficios de la onabotulinumtoxinA, efectos adversos y efectividad frente a otros tratamientos de primera línea. Conclusiones. La onabotulinumtoxinA demostró tener una gran utilidad en el tratamiento de migraña crónica, disminuyendo la frecuencia de cefaleas días-mes, reduciendo la severidad de estas y mejorando la calidad de vida. Además, se evidencio menos abandono con onabotulinumtoxinA frente a los tratamientos de primera línea por parte de los pacientes.
Descargas
La descarga de datos todavía no está disponible.
Metrics
Cargando métricas ...
Detalles del artículo
Cómo citar
Armijos Ayala, A. D., & Chunchi Ayala, L. M. (2023). Utilidad de la toxina botulínica en el tratamiento de migraña crónica. Ciencia Digital, 7(1), 97-112. https://doi.org/10.33262/cienciadigital.v7i1.2447
Sección
Artículos
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0.
Citas
Affatato, O., Moulin, T. C., Pisanu, C., Babasieva, V. S., Russo, M., Aydinlar, E. I., & Mwinyi, J. (2021). High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis. Journal of translational medicine, 19(1), 133. doi: https://doi.org/10.1186/s12967-021-02801-w
Aydinlar, E. I., Dikmen, P. Y., Kosak, S., & Kocaman, A. S. (2017). OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states, and sleep quality: a single-center prospective cohort study. The journal of headache and pain, 18(1), 23. doi: https://doi.org/10.1186/s10194-017-0723-4
Blumenfeld, A. M. (2018). Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. The journal of headache and pain, 19(1), 13. doi: https://doi.org/10.1186/s10194-018-0840-8
Blumenfeld, A. M., Patel, A. T., Turner, I. M., Mullin, K. B., Manack Adams, A., & Rothrock, J. F. (2020). Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults with Chronic Migraine. Journal of primary care & community health, 11. doi: https://doi.org/10.1177/2150132720959936
Boudreau, G., Finkelstein, I., Graboski, C., Ong, M., Christie, S., Sommer, K., & Becker, W. J. (2022). OnabotulinumtoxinA improves quality of life in chronic migraine: The PREDICT study. Canadian Journal of Neurological Sciences, 49(4), 540-552. doi:10.1017/cjn.2021.153
Castrillo Sanz, A., Morollón Sánchez-Mateos, N., Simonet Hernández, C., Fernández Rodríguez, B., Cerdán Santacruz, D., Mendoza Rodríguez, A., & Duate García-Luis, J. (2018). Experience with botulinum toxin in chronic migraine. Neurología, 33(8), 499-504. doi: https://doi.org/10.1016/j.nrl.2016.09.004
Do, T. P., Hvedstrup, J., & Schytz, H. W. (2018). Botulinum toxin: A review of the mode of action in migraine. Acta neurologica Scandinavica, 137(5), 442-451. doi: https://doi.org/10.1111/ane.12906
Frampton, J. E., & Silberstein, S. (2018). OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine. Drugs, 78(5), 589-600. doi: https://doi.org/10.1007/s40265-018-0894-6
González-Martínez, A., Planchuelo-Gómez, Á., Guerrero, Á. L., García-Azorín, D., Santos-Lasaosa, S., Navarro-Pérez, M. P., & Gago-Veiga, A. B. (2021). Effects of the onabotulinumtoxinA follow-up delay in migraine course during the COVID-19 lockdown. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 42(12), 5087-5092. doi: https://doi.org/10.1007/s10072-021-05180-8
Gribbin, C. L., Dani, K. A., & Tyagi, A. (2021). Chronic Migraine: An Update on Diagnosis and Management. Neurology India, 69(1), S67-S75. doi: https://doi.org/10.4103/0028-3886.315972
Herd, C. P., Tomlinson, C. L., Rick, C., Scotton, W. J., Edwards, J., Ives, N. J., & Sinclair, A. J. (2019). Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ open, 9(7). doi: https://doi.org/10.1136/bmjopen-2018-027953
Kollewe, K., Gaul, C., Gendolla, A., & Sommer, K. (2021). Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study. The journal of headache and pain, 22(1), 50. doi: https://doi.org/10.1186/s10194-021-01260-4
Martínez-Pías, E., Guerrero, Á. L., Sierra, Á., Trigo, J., & & García-Azorín, D. (2021). Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA. Toxins, 13(6), 432. doi: https://doi.org/10.3390/toxins13060432
Matharu, M., Halker, R., Pozo-Rosich, P., DeGryse, R., Manack Adams, A., & Aurora, S. K. (2017a). The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. The journal of headache and pain, 18(1), 78. doi: https://doi.org/10.1186/s10194-017-0784-4
Matharu, M., Pascual, J., Nilsson Remahl, I., Straube, A., Lum, A., Davar, G., & Johannes, C. (2017b). Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia: an international journal of headache, 37(14), 1384-1397. doi: https://doi.org/10.1177/0333102417724150
Pak, A. T., Üstün, İ., & Sengul, Y. (2021). Botulinum toxin type A wear-off phenomenon in chronic migraine patients: how long does the maximum efficiency last? Arquivos de neuro-psiquiatria, 79(10), 886–890. doi: https://doi.org/10.1590/0004-282X-ANP-2020-0542
Peters, G. L. (2019). Migraine overview and summary of current and emerging treatment options. The American journal of managed care, 25(2), S23-S24.
Ranoux, D., Martiné, G., Espagne-Dubreuilh, G., Amilhaud-Bordier, M., Caire, F., & Magy, L. (2017). OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study. The journal of headache and pain, 18(1), 75. doi: https://doi.org/10.1186/s10194-017-0781-7
Rothrock, J. F., Adams, A. M., Lipton, R. B., Silberstein, S. D., Jo, E., & Zhao, X. (2019). FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults with Chronic Migraine. Headache, 59(10), 1700-1713. doi: https://doi.org/10.1111/head.13653
Ruscheweyh, R., Athwal, B., Gryglas-Dworak, A., Frattale, I., Latysheva, N., Ornello, R., & Stark, C. D. (2020). Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review with Analysis of Headache Diaries. Headache, 60(8), 1673–1682. doi: https://doi.org/10.1111/head.13925
Santoro, A., Copetti, M., Miscio, A. M., Leone, M. A., & Fontana, A. (2020). Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 41(7), 1809-1820. Doi: Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Shaterian, N., Shaterian, N., Ghanaatpisheh, A., Abbasi, F., Daniali, S., Jahromi, M. J., & Abdoli, A. (2022). Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review. Pain research & management. doi: https://doi.org/10.1155/2022/3284446
Shen, B., & Wang, L. (2020). Impact of the botulinum-A toxin on prevention of adult migraine disorders. Journal of integrative neuroscience, 19(1), 201-208. doi: https://doi.org/10.31083/j.jin.2020.01.1240
Stark, C., Stark, R., Limberg, N., Rodrigues, J., Cordato, D., Schwartz, R., & Jukic, R. (2019). Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study. The journal of headache and pain, 20(1), 81. doi: https://doi.org/10.1186/s10194-019-1030-z
Tassorelli, C., Aguggia, M., De Tommaso, M., Geppetti, P., Grazzi, L., Pini, L. A., & Cortelli, P. (2017). Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers. The journal of headache and pain, 18(1), 66. doi: https://doi.org/10.1186/s10194-017-0773-7
Tassorelli, C., Tedeschi, G., Sarchielli, P., Pini, L. A., Grazzi, L., Geppetti, P., & Martelletti, P. (2018). Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. Expert review of neurotherapeutics, 18(2), 167-176. doi: https://doi.org/10.1080/14737175.2018.1419867
Torres-Ferrus, M., Gallardo, V. J., Alpuente, A., & & Pozo-Rosich, P. (2020). influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. The journal of headache and pain, 21(1), 88. doi: https://doi.org/10.1186/s10194-020-01157-8
Vikelis, M., Argyriou, A. A., Dermitzakis, E. V., Spingos, K. C., Makris, N., & Kararizou, E. (2018). Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment. The journal of headache and pain, 19(1), 87. doi: https://doi.org/10.1186/s10194-018-0918-3
Winner, P. K., Kabbouche, M., Yonker, M., Wangsadipura, V., Lum, A., & Brin, M. F. (2020). A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents with Chronic Migraine. Headache, 60(3), 564-575. doi: https://doi.org/10.1111/head.13754
Wong, H. T., Khalil, M., & Ahmed, F. (2020). OnabotulinumtoxinA for chronic migraine during pregnancy: a real-world experience on 45 patients. The journal of headache and pain, 21(1), 129. doi: https://doi.org/10.1186/s10194-020-01196-1
Aydinlar, E. I., Dikmen, P. Y., Kosak, S., & Kocaman, A. S. (2017). OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states, and sleep quality: a single-center prospective cohort study. The journal of headache and pain, 18(1), 23. doi: https://doi.org/10.1186/s10194-017-0723-4
Blumenfeld, A. M. (2018). Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. The journal of headache and pain, 19(1), 13. doi: https://doi.org/10.1186/s10194-018-0840-8
Blumenfeld, A. M., Patel, A. T., Turner, I. M., Mullin, K. B., Manack Adams, A., & Rothrock, J. F. (2020). Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults with Chronic Migraine. Journal of primary care & community health, 11. doi: https://doi.org/10.1177/2150132720959936
Boudreau, G., Finkelstein, I., Graboski, C., Ong, M., Christie, S., Sommer, K., & Becker, W. J. (2022). OnabotulinumtoxinA improves quality of life in chronic migraine: The PREDICT study. Canadian Journal of Neurological Sciences, 49(4), 540-552. doi:10.1017/cjn.2021.153
Castrillo Sanz, A., Morollón Sánchez-Mateos, N., Simonet Hernández, C., Fernández Rodríguez, B., Cerdán Santacruz, D., Mendoza Rodríguez, A., & Duate García-Luis, J. (2018). Experience with botulinum toxin in chronic migraine. Neurología, 33(8), 499-504. doi: https://doi.org/10.1016/j.nrl.2016.09.004
Do, T. P., Hvedstrup, J., & Schytz, H. W. (2018). Botulinum toxin: A review of the mode of action in migraine. Acta neurologica Scandinavica, 137(5), 442-451. doi: https://doi.org/10.1111/ane.12906
Frampton, J. E., & Silberstein, S. (2018). OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine. Drugs, 78(5), 589-600. doi: https://doi.org/10.1007/s40265-018-0894-6
González-Martínez, A., Planchuelo-Gómez, Á., Guerrero, Á. L., García-Azorín, D., Santos-Lasaosa, S., Navarro-Pérez, M. P., & Gago-Veiga, A. B. (2021). Effects of the onabotulinumtoxinA follow-up delay in migraine course during the COVID-19 lockdown. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 42(12), 5087-5092. doi: https://doi.org/10.1007/s10072-021-05180-8
Gribbin, C. L., Dani, K. A., & Tyagi, A. (2021). Chronic Migraine: An Update on Diagnosis and Management. Neurology India, 69(1), S67-S75. doi: https://doi.org/10.4103/0028-3886.315972
Herd, C. P., Tomlinson, C. L., Rick, C., Scotton, W. J., Edwards, J., Ives, N. J., & Sinclair, A. J. (2019). Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ open, 9(7). doi: https://doi.org/10.1136/bmjopen-2018-027953
Kollewe, K., Gaul, C., Gendolla, A., & Sommer, K. (2021). Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study. The journal of headache and pain, 22(1), 50. doi: https://doi.org/10.1186/s10194-021-01260-4
Martínez-Pías, E., Guerrero, Á. L., Sierra, Á., Trigo, J., & & García-Azorín, D. (2021). Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA. Toxins, 13(6), 432. doi: https://doi.org/10.3390/toxins13060432
Matharu, M., Halker, R., Pozo-Rosich, P., DeGryse, R., Manack Adams, A., & Aurora, S. K. (2017a). The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. The journal of headache and pain, 18(1), 78. doi: https://doi.org/10.1186/s10194-017-0784-4
Matharu, M., Pascual, J., Nilsson Remahl, I., Straube, A., Lum, A., Davar, G., & Johannes, C. (2017b). Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia: an international journal of headache, 37(14), 1384-1397. doi: https://doi.org/10.1177/0333102417724150
Pak, A. T., Üstün, İ., & Sengul, Y. (2021). Botulinum toxin type A wear-off phenomenon in chronic migraine patients: how long does the maximum efficiency last? Arquivos de neuro-psiquiatria, 79(10), 886–890. doi: https://doi.org/10.1590/0004-282X-ANP-2020-0542
Peters, G. L. (2019). Migraine overview and summary of current and emerging treatment options. The American journal of managed care, 25(2), S23-S24.
Ranoux, D., Martiné, G., Espagne-Dubreuilh, G., Amilhaud-Bordier, M., Caire, F., & Magy, L. (2017). OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study. The journal of headache and pain, 18(1), 75. doi: https://doi.org/10.1186/s10194-017-0781-7
Rothrock, J. F., Adams, A. M., Lipton, R. B., Silberstein, S. D., Jo, E., & Zhao, X. (2019). FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults with Chronic Migraine. Headache, 59(10), 1700-1713. doi: https://doi.org/10.1111/head.13653
Ruscheweyh, R., Athwal, B., Gryglas-Dworak, A., Frattale, I., Latysheva, N., Ornello, R., & Stark, C. D. (2020). Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review with Analysis of Headache Diaries. Headache, 60(8), 1673–1682. doi: https://doi.org/10.1111/head.13925
Santoro, A., Copetti, M., Miscio, A. M., Leone, M. A., & Fontana, A. (2020). Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 41(7), 1809-1820. Doi: Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Shaterian, N., Shaterian, N., Ghanaatpisheh, A., Abbasi, F., Daniali, S., Jahromi, M. J., & Abdoli, A. (2022). Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review. Pain research & management. doi: https://doi.org/10.1155/2022/3284446
Shen, B., & Wang, L. (2020). Impact of the botulinum-A toxin on prevention of adult migraine disorders. Journal of integrative neuroscience, 19(1), 201-208. doi: https://doi.org/10.31083/j.jin.2020.01.1240
Stark, C., Stark, R., Limberg, N., Rodrigues, J., Cordato, D., Schwartz, R., & Jukic, R. (2019). Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study. The journal of headache and pain, 20(1), 81. doi: https://doi.org/10.1186/s10194-019-1030-z
Tassorelli, C., Aguggia, M., De Tommaso, M., Geppetti, P., Grazzi, L., Pini, L. A., & Cortelli, P. (2017). Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers. The journal of headache and pain, 18(1), 66. doi: https://doi.org/10.1186/s10194-017-0773-7
Tassorelli, C., Tedeschi, G., Sarchielli, P., Pini, L. A., Grazzi, L., Geppetti, P., & Martelletti, P. (2018). Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. Expert review of neurotherapeutics, 18(2), 167-176. doi: https://doi.org/10.1080/14737175.2018.1419867
Torres-Ferrus, M., Gallardo, V. J., Alpuente, A., & & Pozo-Rosich, P. (2020). influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. The journal of headache and pain, 21(1), 88. doi: https://doi.org/10.1186/s10194-020-01157-8
Vikelis, M., Argyriou, A. A., Dermitzakis, E. V., Spingos, K. C., Makris, N., & Kararizou, E. (2018). Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment. The journal of headache and pain, 19(1), 87. doi: https://doi.org/10.1186/s10194-018-0918-3
Winner, P. K., Kabbouche, M., Yonker, M., Wangsadipura, V., Lum, A., & Brin, M. F. (2020). A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents with Chronic Migraine. Headache, 60(3), 564-575. doi: https://doi.org/10.1111/head.13754
Wong, H. T., Khalil, M., & Ahmed, F. (2020). OnabotulinumtoxinA for chronic migraine during pregnancy: a real-world experience on 45 patients. The journal of headache and pain, 21(1), 129. doi: https://doi.org/10.1186/s10194-020-01196-1